Orbit Discovery, an Oxford, England, UK-based biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, raised $7.6m (USD) in funding.
The financing was led by Oxford Sciences Innovation, with participation from Borealis Ventures, Perivoli Innovations, and other institutional and individual investors, including Kapil Dev Joory.
Proceeds from the financing will be used to accelerate the company’s growth.
Led by Dr. Neil Butt, Chief Executive Officer, Orbit is a provider of peptide discovery services to the biotechnology and pharmaceutical industry. Its novel bead-based and microfluidic technology platform enables the screening of peptide libraries for target binding and subsequent activity in cell-based functional assays. This enables the platform to identify active peptides against both soluble proteins and membrane bound targets such as GPCRs.